209 related articles for article (PubMed ID: 30410484)
1. A Natural Variant of the Signaling Molecule Vav1 Enhances Susceptibility to Myasthenia Gravis and Influences the T Cell Receptor Repertoire.
Bernard I; Sacquin A; Kassem S; Benamar M; Colacios C; Gador M; Pérals C; Fazilleau N; Saoudi A
Front Immunol; 2018; 9():2399. PubMed ID: 30410484
[TBL] [Abstract][Full Text] [Related]
2. A Natural Variant of the T Cell Receptor-Signaling Molecule Vav1 Reduces Both Effector T Cell Functions and Susceptibility to Neuroinflammation.
Kassem S; Gaud G; Bernard I; Benamar M; Dejean AS; Liblau R; Fournié GJ; Colacios C; Malissen B; Saoudi A
PLoS Genet; 2016 Jul; 12(7):e1006185. PubMed ID: 27438086
[TBL] [Abstract][Full Text] [Related]
3. T cells and cytokines in the pathogenesis of acquired myasthenia gravis.
Milani M; Ostlie N; Wang W; Conti-Fine BM
Ann N Y Acad Sci; 2003 Sep; 998():284-307. PubMed ID: 14592887
[TBL] [Abstract][Full Text] [Related]
4. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells.
Wang W; Milani M; Ostlie N; Okita D; Agarwal RK; Caspi RR; Conti-Fine BM
J Immunol; 2007 Jun; 178(11):7072-80. PubMed ID: 17513756
[TBL] [Abstract][Full Text] [Related]
5. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis.
Balasa B; Deng C; Lee J; Christadoss P; Sarvetnick N
J Immunol; 1998 Sep; 161(6):2856-62. PubMed ID: 9743346
[TBL] [Abstract][Full Text] [Related]
6. IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis.
Schaffert H; Pelz A; Saxena A; Losen M; Meisel A; Thiel A; Kohler S
Eur J Immunol; 2015 May; 45(5):1339-47. PubMed ID: 25676041
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis.
Wang HB; Li H; Shi FD; Chambers BJ; Link H; Ljunggren HG
Int Immunol; 2000 Oct; 12(10):1381-8. PubMed ID: 11007755
[TBL] [Abstract][Full Text] [Related]
8. Decreased bone mineral density in experimental myasthenia gravis in C57BL/6 mice.
Oshima M; Iida-Klein A; Maruta T; Deitiker PR; Atassi MZ
Autoimmunity; 2017 Sep; 50(6):346-353. PubMed ID: 28850269
[TBL] [Abstract][Full Text] [Related]
9. Positive regulation of Vav1 by Themis controls CD4 T cell pathogenicity in a mouse model of central nervous system inflammation.
Marrocco R; Bernard I; Joulia E; Barascud R; Dejean AS; Lesourne R; Saoudi A
Cell Mol Life Sci; 2024 Apr; 81(1):161. PubMed ID: 38565808
[TBL] [Abstract][Full Text] [Related]
10. Animal models of myasthenia gravis.
Christadoss P; Poussin M; Deng C
Clin Immunol; 2000 Feb; 94(2):75-87. PubMed ID: 10637092
[TBL] [Abstract][Full Text] [Related]
11. The N-terminal 20-amino acid region of guanine nucleotide exchange factor Vav1 plays a distinguished role in T cell receptor-mediated calcium signaling.
Li SY; Du MJ; Wan YJ; Lan B; Liu YH; Yang Y; Zhang CZ; Cao Y
J Biol Chem; 2013 Feb; 288(6):3777-85. PubMed ID: 23271736
[TBL] [Abstract][Full Text] [Related]
12. The I-Abm12 mutation, which confers resistance to experimental myasthenia gravis, drastically affects the epitope repertoire of murine CD4+ cells sensitized to nicotinic acetylcholine receptor.
Bellone M; Ostlie N; Lei SJ; Wu XD; Conti-Tronconi BM
J Immunol; 1991 Sep; 147(5):1484-91. PubMed ID: 1715360
[TBL] [Abstract][Full Text] [Related]
13. T cell responses in EAMG-susceptible and non-susceptible mouse strains after immunization with overlapping peptides encompassing the extracellular part of Torpedo californica acetylcholine receptor alpha chain. Implication to role in myasthenia gravis of autoimmune T-cell responses against receptor degradation products.
Oshima M; Yokoi T; Deitiker P; Atassi MZ
Autoimmunity; 1998; 27(2):79-90. PubMed ID: 9583739
[TBL] [Abstract][Full Text] [Related]
14. Experimental myasthenia gravis in congenic mice. Sequence mapping and H-2 restriction of T helper epitopes on the alpha subunits of Torpedo californica and murine acetylcholine receptors.
Bellone M; Ostlie N; Lei S; Conti-Tronconi BM
Eur J Immunol; 1991 Oct; 21(10):2303-10. PubMed ID: 1680694
[TBL] [Abstract][Full Text] [Related]
15. An Epistatic Interaction between Themis1 and Vav1 Modulates Regulatory T Cell Function and Inflammatory Bowel Disease Development.
Pedros C; Gaud G; Bernard I; Kassem S; Chabod M; Lagrange D; Andréoletti O; Dejean AS; Lesourne R; Fournié GJ; Saoudi A
J Immunol; 2015 Aug; 195(4):1608-16. PubMed ID: 26163585
[TBL] [Abstract][Full Text] [Related]
16. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice.
Balasa B; Deng C; Lee J; Bradley LM; Dalton DK; Christadoss P; Sarvetnick N
J Exp Med; 1997 Aug; 186(3):385-91. PubMed ID: 9236190
[TBL] [Abstract][Full Text] [Related]
17. Both CD4+ and CD8+ T cells are essential to induce experimental autoimmune myasthenia gravis.
Zhang GX; Xiao BG; Bakhiet M; van der Meide P; Wigzell H; Link H; Olsson T
J Exp Med; 1996 Aug; 184(2):349-56. PubMed ID: 8760788
[TBL] [Abstract][Full Text] [Related]
18. Preferential use of a T cell receptor V beta gene by acetylcholine receptor reactive T cells from myasthenia gravis-susceptible mice.
Infante AJ; Levcovitz H; Gordon V; Wall KA; Thompson PA; Krolick KA
J Immunol; 1992 Jun; 148(11):3385-90. PubMed ID: 1375242
[TBL] [Abstract][Full Text] [Related]
19. Injection of inactive Bordetella pertussis and complete Freund's adjuvant with Torpedo californica AChR increases the occurrence of experimental autoimmune myasthenia gravis in C57BL/6 mice.
Maruta T; Oshima M; Mosier DR; Atassi MZ
Autoimmunity; 2017 Aug; 50(5):293-305. PubMed ID: 28548588
[TBL] [Abstract][Full Text] [Related]
20. ICOS is essential for the development of experimental autoimmune myasthenia gravis.
Scott BG; Yang H; Tüzün E; Dong C; Flavell RA; Christadoss P
J Neuroimmunol; 2004 Aug; 153(1-2):16-25. PubMed ID: 15265659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
